Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing timecourse of murine hepatocytes with or without paracetamol treatment

ABSTRACT: Next Generation Sequencing timecourse of murine hepatocytes with or without paracetamol treatment

PROVIDER: PRJNA547765 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9214680_1.fastq.gz	Fastqsanger.gz
	SRR9214680_2.fastq.gz	Fastqsanger.gz
	SRR9214690_1.fastq.gz	Fastqsanger.gz
	SRR9214690_2.fastq.gz	Fastqsanger.gz
	SRR9214700_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Next Generation Sequencing timecourse of murine hepatocytes with or without paracetamol treatment

Project description:Untreated mice or mice treated with paracetamol, in the presence or absence of TSA, were culled after 14 hrs or 24 hrs of treatment, and RNAseq was performed. Method: RNA was extracted, in triplicate, then sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Tophat2 and then analysed with Cufflinks.

2020-06-30 | GSE132368 | GEO

Primary Human Hepatocytes with HCVcc infection timecourse

Project description:Goal was to investigate the transcriptional effect of Hepatitis C Virus (HCV) infection upon hepatic gene expression in a primary tissue system. Cultured Primary human hepatocytes were infected with HCV (genotype 2a-JFH1) and maintained through a timecourse in parallel with matched controls of uninfected cells culture.These samples are a subset of a larger experiment to be published at a later date, which also included treatments with Type I and Type II interferons.

2015-01-31 | E-MTAB-2476 | biostudies-arrayexpress

Transcription profiling time series toxicogenomic profiles in CD-1 mice after nontoxic and nonlethal hepatotoxic paracetamol administration

Project description:Effect of vehicle vs non-toxic and toxic paracetamol (151mg/kg and 529mg/kg) doses on the gene expression profile at 1, 4 and 24h in murine liver.

2004-02-20 | E-MEXP-82 | biostudies-arrayexpress

Generic drug screen identifies paracetamol as 5-aza-2’-deoxycytidine sensitizer in head and neck squamous cell carcinoma cells

Project description:Aberrant DNA methylation (5mC) is one of the key characteristics of many cancers including head and neck squamous cell carcinoma (HNSCC). The DNA demethylating agent 5-aza-2’-deoxycytidine (DAC) has anti-cancer therapeutic potential, but its clinical efficacy is currently hindered by dose-limiting side effects. Here we investigated the potential use of DAC in the treatment of HNSCC and show that its efficacy is primarily dependent on the ability of DAC to demethylate DNA. In order to establish whether HNSCC cells can be sensitized to DAC, a panel of 100 generic drugs were screened in combination with DAC. While the 100-drug panel did not sensitise DAC-resistant HNSCC cell lines to DAC treatment, the screen identified that paracetamol (acetaminophen), valproic acid and zinc acetate significantly enhanced DAC efficacy in the DAC-responsive cell lines. DAC and paracetamol were established to work in synergy, allowing DAC to be used at therapeutically relevant low doses (below 500nM). The mechanisms underlying the DAC-paracetamol synergy are multifactorial and encompass both effects of DAC on paracetamol action (alterations in the cyclooxygenase (COX) pathway and mimicry of paracetamol overdose) as well as decreased DNA methylation by paracetamol. Therefore, we propose DAC to be a potential therapeutic in a subset of HNSCC patients with its efficacy significantly increased by use of the common analgesic paracetamol. The DAC-paracetamol synergy should also be considered in cancers with an approved DAC treatment regime.

2018-11-02 | GSE110045 | GEO

Single-cell ATAC-seq analysis of hESCs undergoing neuronal differentiation exposed to paracetamol [scATAC-seq]

Project description:Genome-wide chromatin opening profiling of hESCs undergoing neuronal differentiation at four distinct time-points. hESCs are differentiated using a neuronal protocol, and day 20 were charachterized. Cells exposed to 100 or 200 μM paracetamol from Day 1.

2023-08-31 | GSE220026 | GEO

Gene expression analysis of hESCs undergoing neuronal differentiation exposed to paracetamol [RNA-seq]

Project description:Genome-wide gene expression profiling of hESCs undergoing neuronal differentiation at four distinct time-points. hESCs are differentiated using a neuronal differentiation protocol, day 7 and 20 were charachterized. Cells were exposed to 100 or 200 μM paracetamol from Day 1 were charachterised at Day 7 and Day 20.

2023-08-31 | GSE220024 | GEO

Quantitative timecourse proteomics analysis of oncogenic KRAS removal in mouse Pancreatic Ductal Adenocarcinoma Cells

Project description:To reveal the impact of mutant KRAS on the proteome of Pancreatic Ductal Adenocarcinoma (PDAC) cells, we carried out a quantitative phospho-proteomic analysis of tumour cells isolated from an inducible mouse model of PDAC (iKras PDAC) (Ying et al., 2012). In this model, oncogenic Kras (G12D) expression can be controlled by administration of doxycycline (Dox). A timecourse Dox removal experiment was carried out in which cells with or without Dox removal at 12, 24, 36, and 48 hrs intervals were lysed and analysed by quantitative proteomics using Tandem Mass Tagging (TMT). Two independent biological replicate experiments were carried out, with timecourse samples in each replicate being barcoded and pooled together using TMT 10plex labelling kit (Thermo).

2023-02-12 | PXD038441 | Pride

HeLa Adenovirus timecourse

Project description:HeLa Adenovirus timecourse

| PRJEB3253 | ENA

Meiosis timecourse Rap1

Project description:Meiosis timecourse Rap1

| PRJNA302914 | ENA

Chromatin occupancy and target genes of TCF7L2 in hepatocytes

Project description:TCF7L2 regulates multiple metabolic pathways in hepatocytes through a transcriptional network involving HNF4M-NM-1 For the identification of Tcf7l2 target genes using a RNA-seq timecourse, and for identifying the binding sites of Tcf7l2 and Hnf4a, Tcf7l2 was silenced in rat H4IIE hepatocytes using siRNA for Tcf7l2 with a scrambled siRNA as control. Treatment times for RNA-seq samples were 3, 6, 9, 12, 15, 18, 48, and 96 hours, and for ChIP-seq samples 15 h. RNA-seq timecourse was performed in duplicate or triplicate, and the ChIP-seq in duplicate for Tcf7l2 and in singlicate for Hnf4a. The H4IIE-specific transcriptome was defined from an independent set of pooled 24 h siRNA treated samples (N=3 for siRNA for Tcf7l2 and N=3 for scrambled siRNA).

2014-11-24 | E-GEOD-53862 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data